
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. boasts a proprietary metagenomics-derived genome editing toolbox that enables precise therapeutic interventions, showcasing promising advancements in treating genetic disorders through its pipeline, including Hemophilia A and other significant conditions. The company's gene editing approach has demonstrated impressive durability, achieving FVIII levels of 80% at the 19-month mark in preclinical models, highlighting its potential for long-term therapeutic effectiveness. Additionally, Metagenomi's dual focus on in vivo gene editing and technology out-licensing for ex vivo cell therapy positions the company favorably to capitalize on the growing demand for innovative genetic medicines.
Bears say
Metagenomi Inc reported a notable net loss of $19.9 million for the second quarter of 2025, equating to a loss of $0.54 per share. The company faces significant risks that could adversely affect its financial prospects, including potential delays in advancing pipeline candidates through clinical assessments, failure to produce favorable clinical data, especially for key programs such as Hemophilia A, and the risk of long-term dilution. Despite trading below its cash value, the combination of these risks contributes to a negative outlook for Metagenomi's stock performance.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares